Q-omics provides the consensus-scored LPO profile across patient tissues and cancer cell-line models. LPO expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LPO is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, LPO RNA expression shows 13,327 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, COAD, and TGCT as cancer lineages where LPO shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LPO — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LPO survival associations across molecular data types. LPO RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LPO RNA expression–survival associations across cancer types. High LPO expression shows unfavorable associations in KIRC, KIRP, COAD and KICH, but favorable associations in LGG and LAML. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LPO RNA expression.
This table summarizes LPO tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for LPO. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LPO shows lower tumor expression in HNSC, KICH and KIRC and higher tumor expression in COAD, LUAD and LUSC. The COAD box plot shows higher LPO RNA expression in tumor versus normal tissue (log2 FC = +0.231, t-test p < 0.001).
This table shows molecular features associated with LPO in patient tissues and cancer cell lines. In patient samples, LPO shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, LPO RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
